mTOR Inhibition: A Promise for a Young Heart.
作者信息
Cau Stefany B A, Tostes Rita C
机构信息
Department of Pharmacology, Medical School of Ribeirao Preto Ribeirao Preto, São Paulo, Brazil.
出版信息
Front Physiol. 2012 Feb 22;3:31. doi: 10.3389/fphys.2012.00031. eCollection 2012.
Abstract
摘要
相似文献
1
mTOR Inhibition: A Promise for a Young Heart.
Front Physiol. 2012 Feb 22;3:31. doi: 10.3389/fphys.2012.00031. eCollection 2012.
2
Targeting mTOR in Pancreatic Ductal Adenocarcinoma.
Front Oncol. 2016 Apr 25;6:99. doi: 10.3389/fonc.2016.00099. eCollection 2016.
3
A system to identify inhibitors of mTOR signaling using high-resolution growth analysis in Saccharomyces cerevisiae.
Geroscience. 2017 Aug;39(4):419-428. doi: 10.1007/s11357-017-9988-4. Epub 2017 Jul 13.
4
Inhibition of mTOR in head and neck cancer cells alters endothelial cell morphology in a paracrine fashion.
Mol Carcinog. 2019 Jan;58(1):161-168. doi: 10.1002/mc.22911. Epub 2018 Oct 21.
5
mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy.
Expert Opin Ther Targets. 2011 Jul;15(7):859-72. doi: 10.1517/14728222.2011.575362. Epub 2011 Apr 8.
6
Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.
Curr Cancer Drug Targets. 2009 Mar;9(2):237-49. doi: 10.2174/156800909787580999.
7
mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques.
Atherosclerosis. 2014 Apr;233(2):601-607. doi: 10.1016/j.atherosclerosis.2014.01.040. Epub 2014 Jan 29.
8
Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope.
Cancer Treat Rev. 2013 Aug;39(5):403-12. doi: 10.1016/j.ctrv.2012.12.002. Epub 2013 Jan 23.
9
Growing experience with mTOR inhibitors in pediatric solid organ transplantation.
Pediatr Transplant. 2013 Nov;17(7):694-706. doi: 10.1111/petr.12147. Epub 2013 Sep 4.
10
Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression.
Sci Signal. 2016 Apr 5;9(422):ra34. doi: 10.1126/scisignal.aad5736.
引用本文的文献
1
Vascular aging: facts and factors.
Front Physiol. 2012 Aug 10;3:325. doi: 10.3389/fphys.2012.00325. eCollection 2012.
2
Differential modulation of nitric oxide synthases in aging: therapeutic opportunities.
Front Physiol. 2012 Jun 25;3:218. doi: 10.3389/fphys.2012.00218. eCollection 2012.
本文引用的文献
1
Perspectives of Targeting mTORC1-S6K1 in Cardiovascular Aging.
Front Physiol. 2012 Jan 25;3:5. doi: 10.3389/fphys.2012.00005. eCollection 2012.
2
Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue.
Diabetes. 2010 Jun;59(6):1338-48. doi: 10.2337/db09-1324. Epub 2010 Mar 18.
3
mTOR inhibition: the learning curve in kidney transplantation.
Transpl Int. 2010 May 1;23(5):447-60. doi: 10.1111/j.1432-2277.2010.01051.x. Epub 2010 Feb 3.
4
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.
Nature. 2009 Jul 16;460(7253):392-5. doi: 10.1038/nature08221. Epub 2009 Jul 8.
5
Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients.
Science. 2005 Nov 18;310(5751):1193-6. doi: 10.1126/science.1115535.
6
Overview of caloric restriction and ageing.
Mech Ageing Dev. 2005 Sep;126(9):913-22. doi: 10.1016/j.mad.2005.03.012.
7
A mammalian protein targeted by G1-arresting rapamycin-receptor complex.
Nature. 1994 Jun 30;369(6483):756-8. doi: 10.1038/369756a0.
8
Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.
J Antibiot (Tokyo). 1975 Oct;28(10):721-6. doi: 10.7164/antibiotics.28.721.
Zotero 插件